Compare Stocks: IMGN, ROIV, INSM, and INCY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMGN ImmunoGen	$31.23	$31.23	$3.61 ▼ $31.25	$8.32B	1.18	8.78 million shs	N/A
INCY Incyte	$124.82 +0.8%	$123.62	$82.52 ▼ $132.60	$25.11B	0.77	1.45 million shs	1.43 million shs
INSM Insmed	$117.67 -0.1%	$119.81	$90.39 ▼ $212.75	$25.73B	0.82	2.04 million shs	1.74 million shs
ROIV Roivant Sciences	$36.98 +3.3%	$36.50	$14.86 ▼ $42.50	$25.86B	1.12	10.44 million shs	6.97 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMGN ImmunoGen	0.00%	0.00%	0.00%	0.00%	0.00%
INCY Incyte	0.00%	-1.13%	-0.39%	+8.05%	+49.81%
INSM Insmed	0.00%	-1.81%	-0.60%	+12.50%	-14.01%
ROIV Roivant Sciences	0.00%	-9.98%	+3.14%	+3.08%	+135.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMGN ImmunoGen	$31.23	$31.23	$3.61 ▼ $31.25	$8.32B	1.18	8.78 million shs	N/A
INCY Incyte	$124.82 +0.8%	$123.62	$82.52 ▼ $132.60	$25.11B	0.77	1.45 million shs	1.43 million shs
INSM Insmed	$117.67 -0.1%	$119.81	$90.39 ▼ $212.75	$25.73B	0.82	2.04 million shs	1.74 million shs
ROIV Roivant Sciences	$36.98 +3.3%	$36.50	$14.86 ▼ $42.50	$25.86B	1.12	10.44 million shs	6.97 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMGN ImmunoGen	0.00%	0.00%	0.00%	0.00%	0.00%
INCY Incyte	0.00%	-1.13%	-0.39%	+8.05%	+49.81%
INSM Insmed	0.00%	-1.81%	-0.60%	+12.50%	-14.01%
ROIV Roivant Sciences	0.00%	-9.98%	+3.14%	+3.08%	+135.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMGN ImmunoGen	0.00	N/A	N/A	N/A
INCY Incyte	2.56	Moderate Buy	$124.80	-0.02% Downside
INSM Insmed	3.00	Buy	$201.87	71.56% Upside
ROIV Roivant Sciences	2.85	Moderate Buy	$45.64	23.41% Upside

Current Analyst Ratings Breakdown

Latest IMGN, ROIV, INSM, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	INCY Incyte	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/28/2026	INCY Incyte	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$120.00 ➝ $123.00
9/28/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$150.00 ➝ $152.00
9/24/2026	ROIV Roivant Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/24/2026	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$188.00
9/24/2026	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$188.00
9/22/2026	INCY Incyte	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform	$109.00
9/16/2026	ROIV Roivant Sciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$51.00
9/15/2026	INSM Insmed	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$212.00 ➝ $198.00
9/11/2026	INCY Incyte	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/9/2026	ROIV Roivant Sciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $46.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMGN ImmunoGen	$287.61M	28.91	N/A	N/A	$0.71 per share	43.99
INCY Incyte	$5.14B	4.92	$6.23 per share	20.05	$26.32 per share	4.74
INSM Insmed	$606.42M	42.37	N/A	N/A	$3.46 per share	34.01
ROIV Roivant Sciences	$8.26M	3,233.82	N/A	N/A	$7.35 per share	5.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMGN ImmunoGen	-$222.93M	-$0.31	N/A	84.41	N/A	-25.56%	-22.11%	-13.53%	N/A
INCY Incyte	$1.29B	$7.85	15.90	15.74	3.60	27.71%	29.93%	22.88%	10/27/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	125.18	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest IMGN, ROIV, INSM, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMGN ImmunoGen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMGN ImmunoGen	0.13	5.70	5.65
INCY Incyte	N/A	4.59	4.51
INSM Insmed	0.74	3.72	3.40
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMGN ImmunoGen	90.50%
INCY Incyte	96.97%
INSM Insmed	N/A
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
IMGN ImmunoGen	5.07%
INCY Incyte	16.20%
INSM Insmed	2.10%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMGN ImmunoGen	277	266.26 million	252.76 million	No Data
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable

IMGN, ROIV, INSM, and INCY Headlines

Recent News About These Companies

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

September 28 at 4:01 AM | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

September 27 at 2:54 PM | theglobeandmail.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

September 27 at 2:54 PM | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)

September 24, 2026 | theglobeandmail.com

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

September 24, 2026 | finance.yahoo.com

Roivant's Immunovant Unit to Stop IMVT-1402 Development in Cutaneous Lupus Erythematosus

September 23, 2026 | finance.yahoo.com

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

September 23, 2026 | globenewswire.com

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

September 23, 2026 | globenewswire.com

Transcript : Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2026, Sep-22-2026 12:20 PM

September 22, 2026 | marketscreener.comM

Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test

September 22, 2026 | insidermonkey.com

Head-To-Head Contrast: Roivant Sciences (NASDAQ:ROIV) & Emergent Biosolutions (NYSE:EBS)

September 22, 2026 | americanbankingnews.com

Vivek Ramaswamy Sold an Estimated $1.2B in Stock, Now Could Become the Third-Richest US Elected Official

September 21, 2026 | ibtimes.co.ukI

Vivek Ramaswamy’s $2.3 Billion fortune puts him on track to be one of America’s richest governors

September 21, 2026 | financialexpress.comF

What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data?

September 18, 2026 | finance.yahoo.com

Roivant Shareholders Approve Directors and Governance Matters

September 18, 2026 | tipranks.com

Roivant Sciences (NASDAQ:ROIV) Director Sells 4,938 Shares

September 18, 2026 | insidertrades.com

Stifel initiates coverage of Roivant Sciences with buy rating

September 17, 2026 | msn.com

Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 4,938 Shares of Stock

September 17, 2026 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from Analysts

September 17, 2026 | americanbankingnews.com

California State Teachers Retirement System Raises Holdings in Roivant Sciences Ltd. $ROIV

September 14, 2026 | marketbeat.com

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

September 13, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMGN, ROIV, INSM, and INCY Company Descriptions

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Incyte NASDAQ:INCY

$124.82 +0.93 (+0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$125.09 +0.27 (+0.21%)

As of 07:55 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Insmed NASDAQ:INSM

$117.67 -0.16 (-0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$118.45 +0.78 (+0.66%)

As of 07:57 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Roivant Sciences NASDAQ:ROIV

$36.98 +1.18 (+3.30%)

Closing price 04:00 PM Eastern

Extended Trading

$38.28 +1.30 (+3.53%)

As of 07:48 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMGN, ROIV, INSM, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMGN, ROIV, INSM, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMGN, ROIV, INSM, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMGN, ROIV, INSM, and INCY Company Descriptions

ImmunoGen NASDAQ:IMGN

Incyte NASDAQ:INCY

Insmed NASDAQ:INSM

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMGN, ROIV, INSM, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMGN, ROIV, INSM, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMGN, ROIV, INSM, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMGN, ROIV, INSM, and INCY Company Descriptions

ImmunoGen NASDAQ:IMGN

Incyte NASDAQ:INCY

Insmed NASDAQ:INSM

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools